Clinical Trials Logo

Filter by:
NCT ID: NCT04988711 Completed - Trauma Clinical Trials

Non-invasive Tool for Measuring Hemoglobin in Severe Trauma Patients in the ED

HbOxymeter
Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The development of miniaturized analytical technologies has facilitated the gradual decentralization of part of the laboratory examinations to the patient. In addition, investigators are currently seeing the development of tools for non-invasive measurement of certain biological parameters. Thanks to their ease of use, results are obtained almost immediately and with good performance. These "rapid" tests or techniques should, in theory, reduce the time taken to take charge of patients, particularly in emergencies or in critical situations where the therapeutic decision should be as rapid and efficient as possible. These means, by their ease and speed of results, could be associated with the clinical examination of the practitioner to increase his diagnostic performance.

NCT ID: NCT04982341 Completed - Clinical trials for Hypoxemic Respiratory Failure

HFNC and Prone Positioning in Awake Patients With Severe COVID-19

Start date: September 2, 2020
Phase:
Study type: Observational

The investigators evaluate the effects of High-flow nasal cannula (HFNC) in association with prone in patients with Covid-19 severe ARF.

NCT ID: NCT04961684 Completed - Clinical trials for Onychomycosis of Toenail

Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis

Start date: February 10, 2020
Phase: N/A
Study type: Interventional

The efficacy and safety of Solver Pen (prototype number X92001704) is evaluated in this randomized, open label, controlled, investigator-blinded, comparative clinical trial in 76 patients. Subjects are treated with either the test medical device (Solver Pen) or the comparator (Loceryl, 5% amorolfine), respectively, for a period of 90 days. The primary objective of the investigation is the increase of percentage of healthy surface on the great toenail at study end versus baseline, as evaluated by a blinded investigator. Patients are followed up for a period of 90 days, with visits at D0 (baseline), D30, D60 and D90, respectively.

NCT ID: NCT04914767 Completed - SARS-CoV2 Infection Clinical Trials

Nigella 5 in the Treatment of SARS COV2 (COVID-19)

Nigelle5
Start date: March 1, 2021
Phase: Phase 1
Study type: Interventional

The world is currently facing a crisis because of this potentially fatal situation of the COVID-19 epidemic without proven efficacy for any drug treatment, while the vaccination is not yet. This epidemic is caused by a new betacorona virus, now called SARS-CoV-2. The most common symptoms reported are fever, cough or chest tightness, and dyspnea. Most cases have a mild course

NCT ID: NCT04883203 Completed - Covid19 Clinical Trials

The Effect of Vitamin D Supplementation on COVID-19 Recovery

COVID-VITD
Start date: April 22, 2020
Phase: Phase 3
Study type: Interventional

The COVID-19 caused by SARS-CoV-2 has transmitted quickly as a global public health emergency. The median duration for Sars-CoV-2 carrying in COVID-19 patients was 20 days (IQR 16-28) What is the role of vitamin D supplementation on the recovery time of asymptomatic and pauci-symptomatic COVID-19 subjects? the intervention group will have vitamin D supplementation (200,000 IU / 1 ml of Cholecalciferol (1 ml) Oral form). Control group will have a placebo treatment (physiological saline). the negative RT-PCR date will be compared in the two groups

NCT ID: NCT04878887 Completed - Ultrasonography Clinical Trials

DRA vs PRA for US-guided Radial Artery Catheterization in ICU

Start date: March 26, 2021
Phase: N/A
Study type: Interventional

Patients were randomly divided into two groups: ultrasound-guided (US-guided) in-plane distal radial access (IP-DRA) and in-plane proximal radial access (IP-PRA) catheterization. For IP-DRA , a linear transducer is placed in the radial fossa, which is known as the snuff-box. After obtaining a long-axis view of the radial artery ,the needle is inserted in the midpoint of the small footprint transducer. Then,the needle is advanced under real-time US guidance until visualizing the tip of the needle inside the artery . For IP-PRA , a linear transducer is placed in the standard conventional forearm radial. After obtaining a long-axis view of the radial artery ,the needle is inserted in the midpoint of the small footprint transducer. Then,the needle is advanced under real-time US guidance until visualizing the tip of the needle inside the artery .

NCT ID: NCT04871022 Completed - Uterine Scar Defect Clinical Trials

Double-layer Versus Purse Uterine Closure Techniques : Impact on Residual Myometrial Thickness After Cesarean

Start date: May 15, 2021
Phase: N/A
Study type: Interventional

There are different surgical techniques of uterine closure during cesarean. Currently data suggest that the double layer unlocked closure technique is associated with better uterine scar healing, and this technique is considered the gold standard. This study compares two techniques of uterine closure on myometrium thickness: 1. Double layer unlocked suture; 2. Purse suture of the uterus with a first continuous purse suture of the deep portion of the myometrium and a second unlocked continuous suture including the remaining part of the myometrium. The primary outcome is the mean residual myometrium thickness at the site of the uterine scar evaluated by transvaginal ultrasound at six months after cesarean.

NCT ID: NCT04853199 Completed - Clinical trials for SARS (Severe Acute Respiratory Syndrome)

Quercetin In The Treatment Of SARS-COV 2

QUERCOV
Start date: June 1, 2021
Phase: Early Phase 1
Study type: Interventional

In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties. Originally, he gave the flavonoids the name "vitamin P" because of their effectiveness in reducing the permeability of blood vessels. This name was abandoned when it was realized that these substances were not really vitamins. Quercetin is extracted from a variety of plant sources, including the onion peel and the seeds and pods of Dimorphandra mollis, a legume tree native to South America. Although we are far from knowing everything about quercetin, its antioxidant, anti-inflammatory, and antihistamine (antiallergic) properties have been observed in numerous in vitro and animal studies.

NCT ID: NCT04851821 Completed - Clinical trials for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)

Quercetix
Start date: January 4, 2021
Phase: Phase 1
Study type: Interventional

Quercetin is one of the flavonoids. Quercetin as well as rutin are recognized to be among the most active of the flavonoids. It is to quercetin that several medicinal plants, including ginkgo and St. John's Wort, owe part of their therapeutic effects. Often combined with vitamin C in supplements, it improves absorption by the body and delays its elimination. Quercetin is extracted from a variety of plant sources, including the onion peel and seeds and pods of Dimorphandra mollis, a tree in the legume family native to South America. At present, there is no scientific data to demonstrate the effectiveness of herbal medicine, regardless of the plant, to prevent or treat COVID-19. On the other hand, some plant-based food supplements have anti-inflammatory or immunomodulatory properties that may disrupt inflammatory defense mechanisms useful in fighting infections, and in particular against COVID-19.

NCT ID: NCT04826120 Completed - Epidural; Analgesia Clinical Trials

Continuous Versus Intermittent Administration of Epidural Analgesia During Labor

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

prospective randomized single blind study, including full term adult parturients, ASA 2, 3 status, scheduled for vaginal delivery. patients were randomized at 3 cm of cervix dilatation, into 2 groups. Epidural analgesia was initiated and maintained with a solution of Bupivacaine 0,125% and Sufentanil 0,25 mcg/ml. After an initial bolus of 16 ML, patients were randomly assigned to receive intermittent boluses of 8 ml every 60 minutes after the initial dose followed by supplementary PCEA boluses of 8 ml for the first group ( PCEA group) or a continuous epidural infusion at the rate of 8 ml/h adjustable and starting immediately after The initial bolus of 16 ml for patients of the second group (CEI Group).